Jasper Therapeutics Launches Warrant Buyback at $0.324 Each
Jasper Therapeutics is offering to buy back all outstanding warrants at $0.324 each to reduce shareholder dilution and clarify its capital structure.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced Wednesday it has launched a tender offer to repurchase all of its outstanding warrants, paying $0.324 in cash per warrant with no interest, as the Redwood City, Calif.-based biotechnology company moves to simplify its equity structure.
The warrants targeted in the offer were originally issued during an underwritten public offering on September 18, 2025. Any warrants successfully tendered will be retired and permanently cancelled, removing them from the company's capitalization table entirely.
Read more SOS Limited Posts Interim Financial Results for First Half 2026 →
Jasper said the primary rationale for the buyback is to limit the potential dilutive effect those warrants would have had on existing shareholders had they been exercised for shares of common stock, which carries a par value of $0.0001 per share. By retiring the instruments outright, the company aims to give current shareholders and prospective investors clearer visibility into how many shares could ultimately be outstanding.
The move is a common strategic tool for clinical-stage biotechnology firms, which frequently carry complex capital structures built up through successive financing rounds. Reducing the overhang of convertible instruments such as warrants can improve investor confidence and sometimes support a company's stock valuation ahead of future fundraising or partnership discussions. Jasper focuses on therapies targeting immune-mediated diseases.
Continue reading at GlobeNewswire - Industry News on Financial Services
